foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi
Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier
{"title":"foliküler lenfomali{dotless} ve küçük lenfositik lenfomali{dotless} hastalarda nötropenik olmayan enfeksiyon i{dotless}nsidansi{dotless}: Rituximab tedavisinin etkisi","authors":"Rezwan Islam, Mahbubur Rahman, M. A. H. Mian, Hilmi Ege, Douglas Reding, Abdus Shakoor, Hong Liang, Richard J. Mercier","doi":"10.4999/UHOD.11035","DOIUrl":null,"url":null,"abstract":"Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.","PeriodicalId":49402,"journal":{"name":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uhod-Uluslararasi Hematoloji-Onkoloji Dergisi","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4999/UHOD.11035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with indolent and aggressive forms of non-Hodgkin’s lymphoma and has become part of the standard therapy for patients with B-cell malignancies. The study was designed to examine if rituximab increases the risk to develop non-neutropenic infection (NNI). Medical records of 202 patients diagnosed as follicular lymphoma or small lymphocytic lymphoma were reviewed. Negative binomial regression was used to estimate relative risk (RR) of NNI. Rituximab (n= 41) and non-rituximab (n= 161) groups had a total of 31.636 and 195.691 reviewed patient days, and recorded a total of 67 and 154 infections, respectively. Negative binomial regression analysis revealed significant effects for the treatment (rituximab vs. non-rituximab) and age (p< 0.01). The RRs of viral and bacterial NNI for rituximab group compared to nonrituximab group were 3.33 and 2.60, respectively; while the RRs for one year increment of age were 1.03 and 1.04, respectively. The time-to-first viral and bacterial NNI for rituximab group were significantly faster than non-rituximab group. Rituximab may increase the risk of NNI in patients with follicular lymphoma or small lymphocytic lymphoma.
期刊介绍：
Target of Publication is the public representation of new scientific results of fundamental, problem-oriented, and search scientific investigations; analytical articles and reviews by actual scientific problems of coal mining industry, short reports in the field of coal mining industry, including the results of work of scientific meetings, conferences, summit’s and congresses in the field of mining. The basic purpose of the journal is the promotion of innovative activity in the coal mining industry by highlighting and discussing the results of basic and applied research, the experience in applying results of innovation for the development of the Russian coal mining.
The most important tasks of the journal are: the generalization of scientific and practical achievements of specialists in the field of coal mining industry, specializing in the implementation of promising basic and applied research and development of priorities of high technologies; the scientific concept of the publication; the publication of the latest achievements in the field of innovation in coal mining industry. The journal lays special emphasis on methodical elaborations, analytical investigations in the sphere of coal mining. Targets of Journal are in publication of new results of scientific investigations performed by scientists, post-graduate students, and doctoral candidates performed by from higher schools, Russian Academy of Sciences, other scientific organizations of Russia, CIS countries, and foreign universities
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
